28 May 2017 

Underscoring its commitment to the prosperity and wellbeing of the communities in which it operates, Hikma Pharmaceuticals, the fast growing multinational pharmaceutical group, published a report illustrating its contributions toward the achievement of the United Nation’s Sustainable Development Goals (UN SDGs), a set of 17 goals that aim to end poverty, protect the planet and ensure prosperity for all.

In the Hikma UN SDG report, the Group reviewed its contribution to global sustainability efforts, assessing how its core purpose of providing quality pharmaceuticals at affordable prices, combined with its overarching sustainability strategy, affect Hikma’s ability to drive sustainable development. Publication of the report on 19 May, 2017, coincided with Hikma’s participation in the World Economic Forum (WEF) on the Middle East and North Africa, where it is taking a leadership role in bringing together stakeholders from across the region to address issues such as economic growth, social inclusion and other aspects of sustainable development. 

The UN SDGs, adopted by all members of the UN General Assembly in 2015, serve as a guide for policymakers, civil society and the private sector, laying out goals and targets in a range of social, economic and environmental areas. The report focuses on Hikma’s contribution to the five specific SDGs that are most closely aligned with its business and corporate responsibility (CR) activities around the globe. The selected Goals comprise ‘Goal 3: Good Health and Wellbeing’, ‘Goal 4: Quality Education’, ‘Goal 5: Gender Equality’, ‘Goal 8: Decent Work and Economic Growth’ and ‘Goal 9: Industry, Innovation and Infrastructure.’ The report is available on the official Hikma website under its ‘Sustainability’ section.

As a leading pharmaceutical manufacturer, Hikma strives to serve as a model in the areas of sustainability, ethics, and social outreach. The upcoming report will showcase how the Group’s external and internal activities advance the UN SDGs, thereby illustrating the private sector’s crucial role in creating economic growth and addressing social needs.

Since Hikma’s establishment in 1978, CR has served as an integral part of the Group’s purpose and mission, resulting in a corporate culture in which sustainability, volunteerism and community engagement form the cornerstone of operations.  Continuing in the legacy of the Group’s founder, the late Mr. Samih Darwazah, Hikma continuously strives to enhance the wellbeing of local communities, not only through its core activities, but also by focusing on giving back in areas such as education, women’s empowerment, improving quality of and access to health, and elevating medical awareness.

-End-

About Hikma Pharmaceuticals
Hikma Pharmaceuticals PLC is a fast growing pharmaceutical group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma's operations are conducted through three businesses: “Branded”, “Injectables” and “Generics”, based primarily in the Middle East and North Africa ("MENA") region, where it is a market leader, the United States and Europe. Hikma currently employs over 8,500 staff members worldwide.

For further information and latest news updates, visit www.Hikma.com  or contact:
Hana Darwazeh Ramadan
Email: Media@Hikma.com 
Tel: +962 6 580 2900

FTI Consulting
Manash Bhuyan
Email: manash.bhuyan@fticonsulting.com  
Tel: +971 50 841 9631

© Press Release 2017